Advancing innovative therapeutics that transform patients’ lives

Quince Therapeutics to Acquire EryDel

Quince is pleased to announce that it has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company with an innovative autologous intracellular drug encapsulation (AIDE) technology and a Phase 3 lead asset, EryDex.

EryDex targets a rare fatal pediatric neurological disease, Ataxia-Telangiectasia, which currently has no approved treatments and represents an estimated $1+ billion peak sales opportunity.

Learn more about the EryDel acquisition.

Our pipeline includes a bone-targeting drug platform and precision bone growth molecule NOV004 which is available for out-licensing. NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, resulting in rapid increases in bone density, strength, and expedited healing as demonstrated in extensive preclinical studies.